NDA 020488 · Hospira
Magnesium Sulfate In Dextrose 5% In Plastic Container
Magnesium Sulfate · Injection
Last checked: Nov 19, 2026Latest source record: Apr 16, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Jul 11, 1995
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
102
89 serious, 18 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 24, 2026.
Magnesium Sulfate in 5% Dextrose Injection is indicated for: • Prevention of eclampsia in patients with preeclampsia • Treatment of seizures and prevention of recurrent seizures in patients with eclampsia Magnesium Sulfate in 5% Dextrose Injection is indicated for ( 1 ): • Prevention of eclampsia in patients with preeclampsia ( 1 ) • Treatment of seizures and prevention of recurrent seizures in patients with eclampsia ( 1 )
Mechanism: Magnesium prevents seizures in patients with preeclampsia and controls seizures in patients with eclampsia by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end plate by the motor nerve impulse. Magnesium has a depressant effect on the central nervous system [see Drug Interactions (7) ] . Magnesium acts peripherally to produce vasodilation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 11, 1995 Original approval · Type 3 - New Dosage Form Review
2 products under this application
- MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER · MAGNESIUM SULFATE 1GM/100ML · INJECTABLE, INJECTION · Prescription · TE AP
- MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER · MAGNESIUM SULFATE 2GM/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Magnesium Sulfate In Dextrose 5% In Plastic Container" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective22
- exposure during pregnancy11
- off label use11
- hypermagnesaemia8
- maternal exposure during pregnancy8
- acute kidney injury7
- pulmonary oedema7
- hyperglycaemia6
- bile duct obstruction5
- blood bilirubin increased5
- diarrhoea5
- pyrexia5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 8 |
| 2020 | 1 |
| 2021 | 16 |
| 2022 | 24 |
| 2023 | 17 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 5 |
Recalls
1 FDA enforcement reports for this application.
Mar 6, 2015 · Class I · Terminated
Labeling: Wrong Bar Code: There is a potential for some units to be mislabeled with an incorrect barcode on the immediate container that scans as heparin sodium 2000 USP units/1000 mL in 0.9% in sodium chloride...
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.